Vascular Dementia Clinical Presentation

  • Author: Kannayiram Alagiakrishnan, MD, MBBS, MHA, MPH; Chief Editor: Iqbal Ahmed, MBBS, FRCPsych (UK)   more...
 
Updated: Jan 23, 2012
 

History

Cognitive impairment, acutely or subacutely, after an acute neurologic event with a stepwise progression is a typical history suggestive of vascular dementia. However, this classic history is usually observed with multi-infarct dementia and may not be observed with lacunar state.

  • Binswanger disease
    • The average age of onset is between the fourth and seventh decades of life, and 80% of patients have a history of hypertension.
    • Patients also show progressive motor, cognitive, mood, and behavioral changes over a period of 5-10 years. Mood and behavioral changes are observed early and, in some patients, may be the presenting feature.
    • Patients may be apathetic or abulic.
    • Intellectual deficits are also observed early in the disease, and patients are frequently described as disoriented, having memory deficits, inattentive, and vague.
    • Patients with Binswanger dementia often have early-onset urinary incontinence and gait disturbances.
  • Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy
    • The onset of the disease occurs between the third and fourth decades of life.
    • The clinical picture is similar to Binswanger disease but without a history of hypertension and risk factors for cerebrovascular disease.
  • Vascular dementia in general
    • Health professionals can perform a Mini-Mental Status Exam (MMSE),[11] depression assessment screen using DSM-IV-TR criteria,[12] the Geriatric Depression Scale (GDS),[13] or the Cornell Scale for depression in dementia,[14] They should also assess for suicidal and homicidal risk, if necessary. Health professionals can directly ask patients about suicidal or homicidal ideation (thoughts), intent, and plan.
    • Major depression is widely observed mood disorder in vascular dementia. Elderly demented patients may not endorse depressed mood and may be socially withdrawn with decreased psychomotor activity. Suicidal thoughts, intent, passive wishes to die and feeling that life is not worthy is seen in these patients and they should be followed closely. Suicide attempts were observed in fewer than 1% of patients with dementia, and depression is an important reason for that.[15]
    • Demented patients will develop psychosis, delusions, hallucinations and paranoia at some point in their disease and sometimes agitation can be dangerous when it manifests into abnormal behavior and in rare circumstances can lead to attempts of homicide.
    • The mental status is a bedside or interview assessment and includes the patient's appearance, affect (mood), thoughts (especially the presence of hallucinations and delusions), inquiry into self-destructive behavior, homicidal behavior, judgment, and, in this diagnosis, orientation, immediate, recent, and long-term memory.
    • Patients with vascular dementia commonly have mood and behavioral changes.
    • Severe depression is more common in persons with vascular dementia than in those with AD.
    • In some patients with lacunar state and Binswanger disease, such problems may be more prominent than intellectual deficits.
    • Even psychotic symptoms, particularly delusions, have been described in patients with vascular dementia.
    • Emotional lability may be a prominent symptom in some patients.
    • Executive functioning deficits are seen prior to severe memory loss in the early stages of subcortical vascular cognitive impairment.[16]
Next

Physical

A commonly used cognitive screening tool is the Folstein Mini-Mental State Examination. Patchy defects are present in persons with vascular dementia. The deficits are global in persons with Alzheimer dementia.

  • The Folstein Mini-Mental State Examination is as follows:
    • Orientation: First, ask the patient the date, day, month, year, and season. The maximum score is 5. Second, ask the patient their current location, ie, facility, floor, town, state, and country. The maximum score is 5.
    • Registration: Name 3 objects (eg, ball, flag, door), and ask the patient to repeat them. The maximum score is 3.
    • Attention: Ask the patient to spell the word "world" backwards or to subtract 7 from 100 serially backwards (stop after 5 answers). The maximum score is 5.
    • Recall: Ask the patient to remember the 3 objects from the Registration portion of the test. The maximum score is 3.
    • Language
      • Ask the patient to identify a pencil and a watch. The maximum score is 2.
      • Ask the patient to repeat the phrase "no ifs, ands, or buts." The maximum score is 1.
      • Ask the patient to follow a 3-step command. The maximum score is 3.
      • Ask the patient to read and obey the phrase "close your eyes." The maximum score is 1.
      • Ask the patient to write a sentence. The maximum score is 1.
      • Ask the patient to copy a set of interlocking pentagons. The maximum score is 1.
    • Scoring: The maximum score possible is 30. Generally, any score less than 24 is considered abnormal, but the cutoff varies with the patient's level of education. Because the results for this test can vary over time, and for some people results can vary during the day, record when (ie, the time and date) this test was performed.
  • Several specific diagnostic criteria can be used to diagnose vascular dementia, including the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria, the International Classification of Diseases, Tenth Edition criteria, the National Institute of Neurological Disorders and Stroke-Association International pour la Recherché at L'Enseignement en Neurosciences (NINDS-AIREN) criteria, the Alzheimer's Disease Diagnostic and Treatment Center criteria, and the Hachinski ischemic score.
  • The DSM-IV-TR criteria have good sensitivity but low specificity. A summary of the DSM-IV-TR diagnostic criteria is as follows:
    • The patient has developed multiple cognitive deficits manifesting as both (1) memory impairment and (2) one or more of the following cognitive disturbances: aphasia, apraxia, agnosia, and disturbance in executive functioning.
    • The cognitive deficits in the above criteria cause significant impairment in day-to-day functioning, social or occupational functioning and represent a significant decline from the previous level of functioning.
    • Focal neurologic signs and symptoms or radiologic evidence indicative of cerebrovascular disease are present that are judged to be etiologically related to the dementia.
    • The deficits do not occur exclusively during the course of delirium.
  • The NINDS-AIREN criteria are the most specific of all available criteria and are used most commonly in research. They provide 3 levels of certainty: definite, probable, and possible.
  • Lateralizing signs such as hemiparesis, bradykinesia, hyperreflexia, extensor plantar reflexes, ataxia, pseudobulbar palsy, and gait and swallowing difficulties may be observed.
  • Subcortical vascular dementia signs include balance problems, gait disorder, and urinary incontinence; focal lesions may be subtle.
  • Neuropsychological testing is as follows:
    • Patients with vascular dementia have patchy neuropsychological deficits. With vascular dementia, patients have better free recall and fewer recall intrusions compared with patients with AD. Apathy early in the disease is more suggestive of vascular dementia because it usually occurs in the later stages of AD.
    • Patients with vascular dementia have poor verbal fluency and more perseverative behavior compared with patients with AD. They may even have other signs of executive dysfunction such as cognitive slowing, difficulty in shifting sets, and problems with abstraction. Commonly used mental status tests include the Folstein Mini-Mental State Examination and the Cognitive Abilities Screening Instrument.
    • Some cognitive patterns may help to differentiate vascular dementia clinically from AD. Patients with vascular dementia tend to show greater deficits on measures of frontal executive functioning than patients with AD, whereas patients with AD show greater long-term memory deficits than patients with vascular dementia.
    • Neuropsychological findings vary with the site and severity of cerebrovascular disease.
    • For patients with single or multiple large infarcts, deficits correlate with the site and extent of the infarct.
    • In patients with extensive deep white matter disease, impairments may be observed in tests of psychomotor speed, dexterity, executive function, and motor aspects of speech (eg, dysarthria, reduced verbal output). Patients with subcortical vascular dementia show reduced ability to set and reach goals with mental slowing and gradual executive dysfunction.
  • Behavioral problems assessment: Behavioral disturbances are common in dementia and are associated with adverse outcomes, increased disability, caregiver stress, and earlier institutionalization. Patients should be assessed for the following disturbances:
    • Agitation/aggression: Patient exhibits restlessness, physical agitation, or verbal or sexual aggression. Patient is hard to handle or resistant to care.
    • Hallucinations: Patient sees or hears things that are not there.
    • Delusions/paranoia: Patient harbors false beliefs, is suspicious of family members regarding stealing money or belongings, or suspects neighbors are planning to harm him.
    • Sundowning: Abnormal behaviors typically occur in the late afternoon or evening in a circadian rhythm fashion. Patients may exhibit mood swings, become upset or disoriented, or wander.
Previous
Next

Causes

  • Risk factors for vascular dementia include hypertension, smoking, hypercholesterolemia, diabetes mellitus, and cardiovascular and cerebrovascular disease.
  • A large cohort study published in 2010 followed 21,123 heavy midlife smokers (more than 2 packs per day) for a mean of 23 years. These individuals were found more than 2 decades later to have a greater than 100% increased risk of dementia, Alzheimer disease, and vascular dementia in both sexes and across ethnic groups.[17]
  • Vascular dementia development after stroke can be influenced by many factors. Some of the important factors that can lead to the development of dementia are older age, lower education level, family history of dementia, left-sided lesions, larger lesions, larger periventricular white matter ischemic lesions, and strokes in thalamic artery territory, inferomedian temporal lobes, hippocampus, and watershed infarcts involving superior frontal and parietal regions.[18]
Previous
 
 
Contributor Information and Disclosures
Author

Kannayiram Alagiakrishnan, MD, MBBS, MHA, MPH  Associate Professor, Department of Medicine, Division of Geriatric Medicine, University of Alberta Faculty of Medicine and Dentistry, Canada

Kannayiram Alagiakrishnan, MD, MBBS, MHA, MPH is a member of the following medical societies: American College of Physicians and American Geriatrics Society

Disclosure: Nothing to disclose.

Coauthor(s)

Kamal Masaki, MD  Associate Director of Geriatric Medicine Fellowship, Associate Professor, Department of Internal Medicine, Division of Geriatric Medicine, University of Hawaii, John Burns School of Medicine

Disclosure: Nothing to disclose.

Specialty Editor Board

Mohammed A Memon, MD  Chairman and Attending Geriatric Psychiatrist, Department of Psychiatry, Spartanburg Regional Medical Center

Mohammed A Memon, MD is a member of the following medical societies: American Association for Geriatric Psychiatry, American Medical Association, and American Psychiatric Association

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD  Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Harold H Harsch, MD  Program Director of Geropsychiatry, Department of Geriatrics/Gerontology, Associate Professor, Department of Psychiatry and Department of Medicine, Froedtert Hospital, Medical College of Wisconsin

Harold H Harsch, MD is a member of the following medical societies: American Psychiatric Association

Disclosure: lilly Honoraria Speaking and teaching; Forest Labs None None; Pfizer Grant/research funds Speaking and teaching; Northstar None None; Novartis Grant/research funds research; Pfizer Honoraria Speaking and teaching; Sunovion Speaking and teaching; Otsuke Grant/research funds reseach; GlaxoSmithKline Grant/research funds research; Merck Honoraria Speaking and teaching

Chief Editor

Iqbal Ahmed, MBBS, FRCPsych (UK)  Faculty, Department of Psychiatry, Tripler Army Medical Center; Clinical Professor of Psychiatry, Uniformed Services University of Health Sciences: Clinical Professor of Psychiatry, Clinical Professor of Geriatric Medicine, University of Hawaii, John A Burns School of Medicine

Iqbal Ahmed, MBBS, FRCPsych (UK) is a member of the following medical societies: Academy of Psychosomatic Medicine, American Association for Geriatric Psychiatry, American Neuropsychiatric Association, American Psychiatric Association, American Society of Clinical Psychopharmacology, and Royal College of Psychiatrists

Disclosure: Nothing to disclose.

References
  1. Zhang-Nunes SX, Maat-Schieman ML, van Duinen SG, Roos RA, Frosch MP, Greenberg SM. The cerebral beta-amyloid angiopathies: hereditary and sporadic. Brain Pathol. Jan 2006;16(1):30-9. [Medline].

  2. Schmidtke K, Hull M. Cerebral small vessel disease: how does it progress?. J Neurol Sci. Mar 15 2005;229-230:13-20. [Medline].

  3. Jellinger KA. The enigma of vascular cognitive disorder and vascular dementia. Acta Neuropathol (Berl). Apr 2007;113(4):349-88. [Medline].

  4. Delano-Wood L, Abeles N, Sacco JM, Wierenga CE, Horne NR, Bozoki A. Regional white matter pathology in mild cognitive impairment: differential influence of lesion type on neuropsychological functioning. Stroke. Mar 2008;39(3):794-9. [Medline].

  5. Jurasic MJ, Popovic IM, Morovic S, Trkanjec Z, Seric V, Demarin V. Can beta stiffness index be proposed as risk factor for dementia?. Journal of Neurological Sciences. In press.

  6. Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA. Mar 12 1997;277(10):813-7. [Medline].

  7. Roman GC, Kalaria RN. Vascular determinants of cholinergic deficits in Alzheimer disease and vascular dementia. Neurobiol Aging. Dec 2006;27(12):1769-85. [Medline].

  8. Brodaty H, McGilchrist C, Harris L, Peters KE. Time until institutionalization and death in patients with dementia. Role of caregiver training and risk factors. Arch Neurol. Jun 1993;50(6):643-50. [Medline].

  9. Brunnstrom HR, Englund EM. Cause of death in patients with dementia disorders. Eur J Neurol. Apr 2009;16(4):488-92. [Medline].

  10. Phelan EA, Borson S, Grothaus L, Balch S, Larson EB. Association of incident dementia with hospitalizations. JAMA. Jan 11 2012;307(2):165-72. [Medline].

  11. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. Nov 1975;12(3):189-98. [Medline].

  12. American Psychiatric Association. Diagnosis and Statistical Manual of Mental Disorders. Fourth Edition. Text Revision (DSM-IV-TR). Washington, DC: American Psychiatric Press; 2000.

  13. Yesavage JA, Brink TL, Rose TL, et al. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res. Apr 1983;17:37-49.

  14. Alexopoulos GS, Abrams RC, Young RC, Shamoian CA. Cornell Scale for Depression in Dementia. Biol Psychiatry. Feb 1 1988;23(3):271-84. [Medline].

  15. Schneider B, Maurer K, Frolich L. [Dementia and suicide]. Fortschr Neurol Psychiatr. Apr 2001;69(4):164-9. [Medline].

  16. Price CC, Jefferson AL, Merino JG, Heilman KM, Libon DJ. Subcortical vascular dementia: integrating neuropsychological and neuroradiologic data. Neurology. Aug 9 2005;65(3):376-82. [Medline].

  17. Rusanen M, Kivipelto M, Quesenberry CP Jr, Zhou J, Whitmer RA. Heavy Smoking in Midlife and Long-term Risk of Alzheimer Disease and Vascular Dementia. Arch Intern Med. Oct 25 2010;[Medline].

  18. Roman GC. The epidemiology of vascular dementia. Handbook of Clinical Neurology. 2008;vol. 89(3rd series):639-658.

  19. Nagata K, Maruya H, Yuya H, et al. Can PET data differentiate Alzheimer's disease from vascular dementia?. Ann N Y Acad Sci. Apr 2000;903:252-61. [Medline].

  20. Starkstein SE, Sabe L, Vazquez S, et al. Neuropsychological, psychiatric, and cerebral blood flow findings in vascular dementia and Alzheimer's disease. Stroke. Mar 1996;27(3):408-14. [Medline].

  21. Amenta F, Lanari A, Mignini F, Silvestrelli G, Traini E, Tomassoni D. Nicardipine use in cerebrovascular disease: A review of controlled clinical studies. Journal of the Neurological Sciences. In press.

  22. Seitz DP, Adunuri N, Gill SS, et al. Antidepressants for agitation and psychosis in dementia. Cochrane Database Syst Rev. Feb 16 2011;2:CD008191. [Medline].

  23. Vercambre MN, Grodstein F, Manson JE, Stampfer MJ, Kang JH. Physical activity and cognition in women with vascular conditions. Arch Intern Med. Jul 25 2011;171(14):1244-50. [Medline]. [Full Text].

  24. Shprecher D and Mehta L. The syndrome of delayed post- hypoxic leukoencephalopathy. Neurorehabilitation. 2010;26:65-72.

  25. American Psychiatric Association. Practice guideline for the treatment of patients with Alzheimer's disease and other dementias of late life. American Psychiatric Association. Am J Psychiatry. May 1997;154(5 Suppl):1-39. [Medline].

  26. Ballard C, McKeith I, O'Brien J, et al. Neuropathological substrates of dementia and depression in vascular dementia, with a particular focus on cases with small infarct volumes. Dement Geriatr Cogn Disord. Mar-Apr 2000;11(2):59-65. [Medline].

  27. Caplan LR. Binswanger's disease--revisited. Neurology. Apr 1995;45(4):626-33. [Medline].

  28. Chabriat H, Vahedi K, Iba-Zizen MT, et al. Clinical spectrum of CADASIL: a study of 7 families. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Lancet. Oct 7 1995;346(8980):934-9. [Medline].

  29. Chui HC. Vascular dementia, a new beginning: shifting focus from clinical phenotype to ischemic brain injury. Neurol Clin. 2001;18:951-77.

  30. Cummings JL. Vascular subcortical dementias: clinical aspects. Dementia. May-Aug 1994;5(3-4):177-80. [Medline].

  31. Erkinjuntti T, Kurz A, Gauthier S, Bullock R, Lilienfeld S, Damaraju CV. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet. Apr 13 2002;359(9314):1283-90. [Medline].

  32. European Dementia Study. European Pentoxifylline Multi-Infarct Dementia Study. Eur Neurol. 1996;36(5):315-21. [Medline].

  33. Fagerstrom KO. Reducing the weight gain after stopping smoking. Addict Behav. 1987;12(1):91-3. [Medline].

  34. Grilli M, Pizzi M, Memo M, Spano P. Neuroprotection by aspirin and sodium salicylate through blockade of NF-kappaB activation. Science. Nov 22 1996;274(5291):1383-5. [Medline].

  35. Hachinski VC, Bowler JV. Vascular dementia. Neurology. Oct 1993;43(10):2159-60; discussion 2160-1. [Medline].

  36. Hebert R, Brayne C. Epidemiology of vascular dementia. Neuroepidemiology. 1995;14(5):240-57. [Medline].

  37. in't Veld BA, Ruitenberg A, Hofman A, Stricker BH, Breteler MM. Antihypertensive drugs and incidence of dementia: the Rotterdam Study. Neurobiol Aging. May-Jun 2001;22(3):407-12. [Medline].

  38. Kalaria RN. The role of cerebral ischemia in Alzheimer's disease. Neurobiol Aging. Mar-Apr 2000;21(2):321-30. [Medline].

  39. Kalmijn S, Launer LJ, Ott A, et al. Dietary fat intake and the risk of incident dementia in the Rotterdam Study. Ann Neurol. Nov 1997;42(5):776-82. [Medline].

  40. Meyer JS, Huang J, Chowdhury MH. MRI confirms mild cognitive impairments prodromal for Alzheimer's, vascular and Parkinson-Lewy body dementias. J Neurol Sci. Jun 15 2007;257(1-2):97-104. [Medline].

  41. Meyer JS, Rogers RL, McClintic K, et al. Randomized clinical trial of daily aspirin therapy in multi-infarct dementia. A pilot study. J Am Geriatr Soc. Jun 1989;37(6):549-55. [Medline].

  42. Moretti R, Torre P, Antonello RM. Rivastigmine in subcortical vascular dementia: a randomized, controlled, open 12-month study in 208 patients. Am J Alzheimers Dis Other Demen. Sep-Oct 2003;18(5):265-72. [Medline].

  43. Moretti R, Torre P, Antonello RM, et al. Rivastigmine in vascular dementia. Expert Opin Pharmacother. Jun 2004;5(6):1399-410. [Medline].

  44. Nelson NW. Differential diagnosis of Alzheimer's dementia and vascular dementia. Dis Mon. Mar 2007;53(3):148-51. [Medline].

  45. Premkumar DR, Cohen DL, Hedera P, Friedland RP, Kalaria RN. Apolipoprotein E-epsilon4 alleles in cerebral amyloid angiopathy and cerebrovascular pathology associated with Alzheimer's disease. Am J Pathol. Jun 1996;148(6):2083-95. [Medline].

  46. Sadowski M, Pankiewicz J, Scholtzova H, Li YS, Quartermain D, Duff K, et al. Links between the pathology of Alzheimer's disease and vascular dementia. Neurochem Res. Jun 2004;29(6):1257-66. [Medline].

  47. Skoog I. Status of risk factors for vascular dementia. Neuroepidemiology. 1998;17(1):2-9. [Medline].

  48. Vascular Dementia Conference. Summary of the 1st International Conference on the Development of Drug Treatment for Vascular Dementia. Alzheimer Dis Assoc Disorders. Dec 1999;13, Supplement 3:S1-S206.

  49. Wetterling T, Kanitz RD, Borgis KJ. Comparison of different diagnostic criteria for vascular dementia (ADDTC, DSM-IV, ICD-10, NINDS-AIREN). Stroke. Jan 1996;27(1):30-6. [Medline].

  50. Wilkinson D, Doody R, Helme R. Donepezil in vascular dementia: a randomized, placebo-controlled study. Neurology. Aug 26 2003;61(4):479-86. [Medline].

Previous
Next
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.